Literature DB >> 1335560

Gamma-aminobutyric acid-B (GABAB) binding sites in postmortem suicide brains.

B Arranz1, R Cowburn, A Eriksson, M Vestling, J Marcusson.   

Abstract

Gamma-aminobutyric acid-B (GABAB) binding sites labelled with [3H]GABA were determined in postmortem frontal cortex samples of 20 control subjects and 16 suicides. The suicide group was further subdivided according to the method of suicide and the existence of depressive symptoms prior to death. No significant differences in GABAB binding were found either between overall suicide and control groups or between the control group and the other subgroups (violent suicide, nonviolent suicide, nondepressed and depressed suicide victims). A significant increase in GABAB binding was observed in those individuals dying from carbon monoxide poisoning. It is concluded that although GABAB binding sites are not altered in our suicide group, a presynaptic dysfunction might account for the increased GABAB binding found in the carbon monoxide subgroup.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1335560     DOI: 10.1159/000118893

Source DB:  PubMed          Journal:  Neuropsychobiology        ISSN: 0302-282X            Impact factor:   2.328


  3 in total

Review 1.  The GABAβ receptor as a target for antidepressant drug action.

Authors:  Subroto Ghose; Michelle K Winter; Kenneth E McCarson; Carol A Tamminga; Salvatore J Enna
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

2.  Fluoxetine partly exerts its actions through GABA: a neurochemical evidence.

Authors:  M Zafer Gören; Esra Küçükibrahimoglu; Kemal Berkman; Berna Terzioglu
Journal:  Neurochem Res       Date:  2007-05-08       Impact factor: 3.996

Review 3.  Altered γ-aminobutyric acid neurotransmission in major depressive disorder: a critical review of the supporting evidence and the influence of serotonergic antidepressants.

Authors:  Alan L Pehrson; Connie Sanchez
Journal:  Drug Des Devel Ther       Date:  2015-01-19       Impact factor: 4.162

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.